Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Rises By 49.8%
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Rises By 49.8%
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 77,000 shares, an increase of 49.8% from the June 30th total of 51,400 shares. Based on an average trading volume of 470,600 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.5% of the shares of the company are short sold.
Indaptus治療公司(納斯達克：INDP-GET評級)7月份空頭股數業務大幅增長。截至7月15日，空頭股數共有77,000股，比6月30日的51,400股增加了49.8%。以470,600股的平均成交量計算，目前天數與回補比率為0.2天。該公司約1.5%的股票被賣空。
Insider Transactions at Indaptus Therapeutics
Indaptus治療公司的內幕交易
In other news, CEO Jeffrey A. Meckler bought 19,727 shares of the firm's stock in a transaction dated Monday, June 6th. The stock was bought at an average price of $2.63 per share, for a total transaction of $51,882.01. Following the transaction, the chief executive officer now owns 45,374 shares in the company, valued at $119,333.62. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.30% of the company's stock.
其他新聞方面，首席執行官傑弗裏·A·梅克勒在一筆日期為6月6日星期一的交易中購買了該公司19,727股股票。這隻股票的平均價格為每股2.63美元，總成交額為51,882.01美元。交易完成後，這位首席執行官現在擁有該公司45,374股股票，價值119,333.62美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，用户可以通過這個鏈接訪問微博。內部人士持有該公司3.30%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp acquired a new position in Indaptus Therapeutics during the 1st quarter valued at approximately $41,000. State Street Corp acquired a new position in Indaptus Therapeutics during the 1st quarter valued at approximately $78,000. Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 18.7% during the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock valued at $969,000 after purchasing an additional 38,216 shares during the period. Finally, Investment House LLC boosted its position in Indaptus Therapeutics by 272.8% during the 4th quarter. Investment House LLC now owns 95,629 shares of the company's stock valued at $545,000 after purchasing an additional 69,976 shares during the period. Institutional investors and hedge funds own 22.26% of the company's stock.
一些對衝基金和其他機構投資者最近增持或減持了該股。北方信託公司在第一季度收購了Indaptus治療公司的一個新頭寸，價值約為41,000美元。道富公司在第一季度收購了Indaptus治療公司的一個新頭寸，價值約為78,000美元。先鋒集團在第一季度將其在Indaptus治療公司的地位提高了18.7%。先鋒集團(Vanguard Group Inc.)在此期間又購買了38,216股，目前持有242,235股該公司股票，價值969,000美元。最後，Investment House LLC在第四季度將其在Indaptus Treeutics的地位提高了272.8%。Investment House LLC現在持有該公司95,629股股票，價值545,000美元，在此期間又購買了69,976股。機構投資者和對衝基金持有該公司22.26%的股票。
Indaptus Therapeutics Price Performance
Indaptus治療藥物的性價比
Indaptus Therapeutics (NASDAQ:INDP – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, analysts forecast that Indaptus Therapeutics will post -1.85 EPS for the current year.
Indaptus Treateutics(納斯達克：INDP-GET評級)最近一次發佈收益業績是在5月12日星期四。該公司公佈了該季度每股收益(0.41美元)，低於普遍預期的(0.39美元)和(0.02美元)。分析師預測，作為一個整體，Indaptus治療公司本年度的每股收益將達到1.85美元。
About Indaptus Therapeutics
關於Indaptus Treateutics
(Get Rating)
(獲取評級)
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
Indaptus治療公司是一家臨牀前生物技術公司，開發各種抗癌和抗病毒免疫療法產品。它的主要臨牀腫瘤學候選藥物Decoy20對淋巴瘤、肝細胞腫瘤、結直腸腫瘤和胰腺腫瘤以及乙肝病毒和人類免疫缺陷病毒感染的單一藥物活性和/或聯合治療的持久反應，正在進行I期臨牀試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian's Stock Still Have A Future?
- Inflation Resistant Weyerhaeuser Company Might Get Cheaper
- 免費獲取StockNews.com關於Indaptus治療的研究報告(INDP)
- 高露潔-棕欖增長前景光明
- 深度價值高收益紐威爾品牌已準備好觸底
- 這些股票的表現優於上次衰退時的表現
- Rivian的股票還有前途嗎？
- 抗通脹的魏豪斯公司可能會變得更便宜
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Indaptus治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Indaptus治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。